Jim Cramer: Arrowhead Pharmaceuticals Doesn't 'Have The Horses'

On CNBC's “Mad Money Lightning Round,” Jim Cramer recommended buying Dover Corporation (NYSE:DOV).

Supporting his view, Dover, on April 24, posted better-than-expected earnings for the first quarter.

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) doesn’t make any money, Cramer said. “I just don’t know if it has the horses.”

As per the recent news, Arrowhead Pharmaceuticals, on Monday, initiated Phase 1/2a study of ARO-ALK7 for the treatment of obesity.

Cramer said Snowflake Inc. (NASDAQ:SNOW) CEO Sridhar Ramaswamy is “cerebral, and he's got a real good closing sense, and man, does he ever have momentum.”

Supporting his view, Snowflake, on May 21, reported first-quarter revenue of $1.04 billion, beating analyst estimates of $1.01 billion. The AI data cloud company reported adjusted earnings of 24 cents per share, beating analyst estimates of 21 cents per share, according to Benzinga Pro.

Fluor (NYSE:FLR) is “always a bridesmaid, never a bride,” Cramer said.

On the earnings front, Fluor, on May 2, posted mixed first-quarter 2025 results, with key metrics surpassing some expectations. Fluor’s revenue grew 6.6% year-over-year to $3.982 billion, missing the consensus of $4.18 billion. Adjusted EPS improved to 73 cents from 47 cents a year ago, above the consensus of 50 cents.

Price Action:

• Arrowhead Pharmaceuticals shares gained 1.3% to settle at $16.61 on Tuesday.
• Snowflake shares fell 0.5% to close at $209.15.
• Dover shares gained 1.1% to close at $177.97.
• Fluor shares gained 5.4% to settle at $43.39 on Tuesday.

Read Next:

• Cramer: Should’ve Told Investors To ‘Pull The Trigger’ On Trade Desk, Can’t Believe ‘How Low’ Gentex Has Fallen

Image: Shutterstock